The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans
Open accessAbstract
NY-ESO-1 is a “cancer-testis” antigen expressed in many cancers. ISCOMATRIX is a saponin-based adjuvant that induces antibody and T cell responses. We performed a placebo-controlled clinical trial evaluating the safety and immunogenicity of recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant. Forty-six evaluable patients with resected NY-ESO-1-positive tumors received three doses of vaccine intramuscularly at monthly intervals. The vaccine was well tolerated. We observed high-titer antibody responses, strong delayed-type hypersensitivity reactions, and circulating CD8+ and CD4+ T cells specific for a broad range of NY-ESO-1 epitopes, including known and previously unknown epitopes. In an unplanned analysis, vaccinated patients appeared to have superior clinical outcomes to those treated with placebo or protein alone. The vaccine is safe and highly potent immunologically.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Detection of intracellular cytokines by flow cytometry
Jung, T., Schauer, U., Heusser, C., Neumann, C., & Rieger, C. (1993) · Journal of Immunological Methods · doi:10.1016/0022-1759(93)90158-4 · Cited by 975
Jäger, E., Chen, Y.-T., Drijfhout, J. W., Karbach, J., Ringhoffer, M., Jäger, D., Arand, M., Wada, H., Noguchi, Y., Stockert, E., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.2.265 · Cited by 725
Self-citationA Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens
Stockert, E., Jäger, E., Chen, Y.-T., Scanlan, M. J., Gout, I., Karbach, J., Arand, M., Knuth, A., & Old, L. J. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.8.1349 · Cited by 698
Self-citationThe cancer/testis genes: review, standardization, and commentary.
Scanlan, M. J., Simpson, A. J. G., & Old, L. J. (2004) · PubMed · Cited by 667
Self-citationJäger, E., Gnjatic, S., Nagata, Y., Stockert, E., Jäger, D., Karbach, J., Neumann, A., Rieckenberg, J., Chen, Y.-T., Ritter, G., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.220413497 · Cited by 426
Self-citationMonitoring CD8 T cell responses to NY-ESO-1: Correlation of humoral and cellular immune responses
Jäger, E., Nagata, Y., Gnjatic, S., Wada, H., Stockert, E., Karbach, J., Dunbar, P. R., Lee, S. Y., Jungbluth, A., Jäger, D., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.9.4760 · Cited by 398
Self-citationTao, M.-H., & Levy, R. (1993) · Nature · doi:10.1038/362755a0 · Cited by 302
LAGE-1, a new gene with tumor specificity
Lethé, B., Lucas, S., Michaux, L., Smet, C. D., Godelaine, D., Serrano, A., Plaen, E. D., & Boon, T. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980610)76:6<903::aid-ijc22>3.0.co;2-1 · Cited by 264
Karanikas, V, Hwang, L. A., Pearson, J., Ong, C. S., Apostolopoulos, V, Vaughan, H., Xing, P. X., Jamieson, G., Pietersz, G., Tait, B., et al. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119825 · Cited by 263
Dendritic Cell-Based Xenoantigen Vaccination for Prostate Cancer Immunotherapy
Fong, L., Brockstedt, D., Benike, C., Breen, J. K., Strang, G., Ruegg, C. L., & Engleman, E. G. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.12.7150 · Cited by 252
Cited by
Vaccine Adjuvants: Putting Innate Immunity to Work
Coffman, R. L., Sher, A., & Seder, R. A. (2010) · Immunity · doi:10.1016/j.immuni.2010.10.002 · Cited by 1,924
Cancer/testis antigens, gametogenesis and cancer
Simpson, A. J. G., Caballero, O. L., Jungbluth, A., Chen, Y.-T., & Old, L. J. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1669 · Cited by 1,582
Self-citationTowards personalized, tumour-specific, therapeutic vaccines for cancer
Hu, Z., Ott, P. A., & Wu, C. J. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.131 · Cited by 1,067
HUMAN T CELL RESPONSES AGAINST MELANOMA
Boon, T., Coulie, P. G., Eynde, B. J. V. D., & Bruggen, P. V. D. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090733 · Cited by 651
Nanotechnology in vaccine delivery
Peek, L. J., Middaugh, C. R., & Berkland, C. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.05.017 · Cited by 562
Cancer/testis (CT) antigens: Potential targets for immunotherapy
Caballero, O. L., & Chen, Y. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01303.x · Cited by 554
Self-citationSharma, P., Shen, Y., Wen, S., Yamada, S., Jungbluth, A. A., Gnjatic, S., Bajorin, D. F., Reuter, V. E., Herr, H., Old, L. J., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611618104 · Cited by 526
Self-citationImmune resistance orchestrated by the tumor microenvironment
Gajewski, T. F., Meng, Y., Blank, C., Brown, I., Kacha, A., Kline, J., & Harlin, H. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00442.x · Cited by 437
CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens
Almeida, L. G., Sakabe, N. J., deOliveira, A. R., Silva, M. C. C., Mundstein, A. S., Cohen, T., Chen, Y.-T., Chua, R., Gurung, S., Gnjatic, S., et al. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn673 · Cited by 433
Self-citationNY‐ESO‐1: Review of an Immunogenic Tumor Antigen
(2006) · Advances in Cancer Research · doi:10.1016/s0065-230x(06)95001-5 · Cited by 405
NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
Thomas, R., Al-Khadairi, G., Roelands, J., Hendrickx, W., Dermime, S., Bedognetti, D., & Decock, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00947 · Cited by 393
The biology of cancer testis antigens: Putative function, regulation and therapeutic potential
Fratta, E., Coral, S., Covre, A., Parisi, G., Colizzi, F., Danielli, R., Marie Nicolay, H. J., Sigalotti, L., & Maio, M. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.02.001 · Cited by 375
Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs
Petrovsky, N. (2015) · Drug Safety · doi:10.1007/s40264-015-0350-4 · Cited by 366
Dhodapkar, M. V., Sznol, M., Zhao, B., Wang, D., Carvajal, R. D., Keohan, M. L., Chuang, E., Sanborn, R. E., Lutzky, J., Powderly, J., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008068 · Cited by 365
Gure, A. O., Chua, R., Williamson, B., Gonen, M., Ferrera, C. A., Gnjatic, S., Ritter, G., Simpson, A. J. G., Chen, Y.-T., Old, L. J., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1203 · Cited by 357
Self-citationYuan, J., Gnjatic, S., Li, H., Powel, S., Gallardo, H. F., Ritter, E., Ku, G. Y., Jungbluth, A. A., Segal, N. H., Rasalan, T. S., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810114105 · Cited by 348
Self-citationGenome-wide analysis of cancer/testis gene expression
Hofmann, O., Caballero, O. L., Stevenson, B. J., Chen, Y.-T., Cohen, T., Chua, R., Maher, C. A., Panji, S., Schaefer, U., Kruger, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810777105 · Cited by 336
Self-citationYuan, J., Adamow, M., Ginsberg, B. A., Rasalan, T. S., Ritter, E., Gallardo, H. F., Xu, Y., Pogoriler, E., Terzulli, S. L., Kuk, D., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1110814108 · Cited by 332
Self-citationThe Sentinel Within: Exploiting the Immune System for Cancer Biomarkers
Anderson, K. S., & LaBaer, J. (2005) · Journal of Proteome Research · doi:10.1021/pr0500814 · Cited by 314
Valmori, D., Souleimanian, N. E., Tosello, V., Bhardwaj, N., Adams, S., O'Neill, D., Pavlick, A., Escalon, J. B., Cruz, C. M., Angiulli, A., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703395104 · Cited by 299
Self-citationTargeting dendritic cells with nano-particulate PLGA cancer vaccine formulations
Hamdy, S., Haddadi, A., Hung, R. W., & Lavasanifar, A. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.05.021 · Cited by 298
Particulate vaccines: on the quest for optimal delivery and immune response
De Temmerman, M.-L., Rejman, J., Demeester, J., Irvine, D. J., Gander, B., & De Smedt, S. C. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.04.006 · Cited by 286
Sabbatini, P., Tsuji, T., Ferran, L., Ritter, E., Sedrak, C., Tuballes, K., Jungbluth, A. A., Ritter, G., Aghajanian, C., Bell-McGuinn, K., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2189 · Cited by 272
Self-citationOdunsi, K., Qian, F., Matsuzaki, J., Mhawech-Fauceglia, P., Andrews, C., Hoffman, E. W., Pan, L., Ritter, G., Villella, J., Thomas, B., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703342104 · Cited by 270
Self-citationImmune Suppression in the Tumor Microenvironment
Gajewski, T. F., Meng, Y., & Harlin, H. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000199193.29048.56 · Cited by 265
Recent progress in adjuvant discovery for peptide-based subunit vaccines
Azmi, F., Ahmad Fuaad, A. A. H., Skwarczynski, M., & Toth, I. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.27332 · Cited by 239
“A study conducted by Ebert and coworkers showed that the synthetic peptide antigen derived from NYESO-1 formulated with ISCOMATRIX was successfully taken up by DC and cross-presented to MHC I cells, producing a potent T cell immunity.(99) Quillaja (and its derivatives) are the most common saponins used in ISCOM system…”
BackgroundTherapeutic Cancer Vaccines—T Cell Responses and Epigenetic Modulation
Kartikasari, A. E. R., Prakash, M. D., Cox, M., Wilson, K., Boer, J. C., Cauchi, J. A., & Plebanski, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03109 · Cited by 54
“Furthermore, ISCOMATRIX R © has been used with the recombinant NY-ESO-1 protein in cancer patients to induce T cell immune responses (137, 138), however this vaccine failed to promote an adequate immune response in advanced melanoma patients (139).”
MethodPollack, S. M. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2018.1419068 · Cited by 47
“Delayed type hypersensitivity responses following NY-ESO-1 protein vaccine administration with the adjuvant ISCOMATRIX® have been associated with long-term survival [56,57].”
BackgroundCurrent advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment
Zhou, H., Ma, Y., Liu, F., Li, B., Qiao, D., Ren, P., & Wang, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1255799 · Cited by 46
Albershardt, T. C., Campbell, D. J., Parsons, A. J., Slough, M. M., ter Meulen, J., & Berglund, P. (2016) · Molecular Therapy - Oncolytics · doi:10.1038/mto.2016.10 · Cited by 38
Metadata
- Authors
- Davis, I. D., Chen, W., Jackson, H., Parente, P., Shackleton, M., Hopkins, W., Chen, Q., Dimopoulos, N., Luke, T., Murphy, R., Scott, A. M., Maraskovsky, E., McArthur, G., MacGregor, D., Sturrock, S., Tai, T. Y., Green, S., Cuthbertson, A., Maher, D., Miloradovic, L., Mitchell, S. V., Ritter, G., Jungbluth, A. A., Chen, Y.-T., Gnjatic, S., Hoffman, E. W., Old, L. J., & Cebon, J. S.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2004-07-13
- Volume
- 101
- Issue
- 29
- Pages
- 10697-10702
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2150835657
- Cited by
- 440
- References
- 26
- FWCI
- 12.68
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.